Your browser doesn't support javascript.
A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate.
Sanchez-Felipe, Lorena; Vercruysse, Thomas; Sharma, Sapna; Ma, Ji; Lemmens, Viktor; Van Looveren, Dominique; Arkalagud Javarappa, Mahadesh Prasad; Boudewijns, Robbert; Malengier-Devlies, Bert; Liesenborghs, Laurens; Kaptein, Suzanne J F; De Keyzer, Carolien; Bervoets, Lindsey; Debaveye, Sarah; Rasulova, Madina; Seldeslachts, Laura; Li, Li-Hsin; Jansen, Sander; Yakass, Michael Bright; Verstrepen, Babs E; Böszörményi, Kinga P; Kiemenyi-Kayere, Gwendoline; van Driel, Nikki; Quaye, Osbourne; Zhang, Xin; Ter Horst, Sebastiaan; Mishra, Niraj; Deboutte, Ward; Matthijnssens, Jelle; Coelmont, Lotte; Vandermeulen, Corinne; Heylen, Elisabeth; Vergote, Valentijn; Schols, Dominique; Wang, Zhongde; Bogers, Willy; Kuiken, Thijs; Verschoor, Ernst; Cawthorne, Christopher; Van Laere, Koen; Opdenakker, Ghislain; Vande Velde, Greetje; Weynand, Birgit; Teuwen, Dirk E; Matthys, Patrick; Neyts, Johan; Jan Thibaut, Hendrik; Dallmeier, Kai.
  • Sanchez-Felipe L; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Vercruysse T; Global Virus Network (GVN), Baltimore, MD, USA.
  • Sharma S; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Ma J; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Translational Platform Virology and Chemotherapy (TPVC), KU Leuven, Leuven, Belgium.
  • Lemmens V; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Van Looveren D; Global Virus Network (GVN), Baltimore, MD, USA.
  • Arkalagud Javarappa MP; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Boudewijns R; Global Virus Network (GVN), Baltimore, MD, USA.
  • Malengier-Devlies B; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Liesenborghs L; Global Virus Network (GVN), Baltimore, MD, USA.
  • Kaptein SJF; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • De Keyzer C; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Translational Platform Virology and Chemotherapy (TPVC), KU Leuven, Leuven, Belgium.
  • Bervoets L; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Debaveye S; Global Virus Network (GVN), Baltimore, MD, USA.
  • Rasulova M; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Seldeslachts L; Global Virus Network (GVN), Baltimore, MD, USA.
  • Li LH; KU Leuven Department of Microbiology, Immunology and Transplantation,Rega Institute, Immunity and Inflammation Research Group, Immunobiology Unit, KU Leuven, Leuven, Belgium.
  • Jansen S; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Yakass MB; Global Virus Network (GVN), Baltimore, MD, USA.
  • Verstrepen BE; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Böszörményi KP; Global Virus Network (GVN), Baltimore, MD, USA.
  • Kiemenyi-Kayere G; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • van Driel N; Global Virus Network (GVN), Baltimore, MD, USA.
  • Quaye O; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Zhang X; Global Virus Network (GVN), Baltimore, MD, USA.
  • Ter Horst S; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Mishra N; Global Virus Network (GVN), Baltimore, MD, USA.
  • Deboutte W; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Matthijnssens J; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Translational Platform Virology and Chemotherapy (TPVC), KU Leuven, Leuven, Belgium.
  • Coelmont L; KU Leuven Department of Imaging and Pathology, Biomedical MRI and MoSAIC, KU Leuven, Leuven, Belgium.
  • Vandermeulen C; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Heylen E; Global Virus Network (GVN), Baltimore, MD, USA.
  • Vergote V; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Schols D; Global Virus Network (GVN), Baltimore, MD, USA.
  • Wang Z; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Bogers W; Global Virus Network (GVN), Baltimore, MD, USA.
  • Kuiken T; West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Accra, Ghana.
  • Verschoor E; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands.
  • Cawthorne C; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands.
  • Van Laere K; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands.
  • Opdenakker G; Animal Science Department, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands.
  • Vande Velde G; Global Virus Network (GVN), Baltimore, MD, USA.
  • Weynand B; West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Accra, Ghana.
  • Teuwen DE; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Matthys P; Global Virus Network (GVN), Baltimore, MD, USA.
  • Neyts J; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Jan Thibaut H; Global Virus Network (GVN), Baltimore, MD, USA.
  • Dallmeier K; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
Nature ; 590(7845): 320-325, 2021 02.
Article in English | MEDLINE | ID: covidwho-953381
ABSTRACT
The expanding pandemic of coronavirus disease 2019 (COVID-19) requires the development of safe, efficacious and fast-acting vaccines. Several vaccine platforms are being leveraged for a rapid emergency response1. Here we describe the development of a candidate vaccine (YF-S0) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that uses live-attenuated yellow fever 17D (YF17D) vaccine as a vector to express a noncleavable prefusion form of the SARS-CoV-2 spike antigen. We assess vaccine safety, immunogenicity and efficacy in several animal models. YF-S0 has an excellent safety profile and induces high levels of SARS-CoV-2 neutralizing antibodies in hamsters (Mesocricetus auratus), mice (Mus musculus) and cynomolgus macaques (Macaca fascicularis), and-concomitantly-protective immunity against yellow fever virus. Humoral immunity is complemented by a cellular immune response with favourable T helper 1 polarization, as profiled in mice. In a hamster model2 and in macaques, YF-S0 prevents infection with SARS-CoV-2. Moreover, a single dose conferred protection from lung disease in most of the vaccinated hamsters within as little as 10 days. Taken together, the quality of the immune responses triggered and the rapid kinetics by which protective immunity can be attained after a single dose warrant further development of this potent SARS-CoV-2 vaccine candidate.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Attenuated / Yellow Fever Vaccine / COVID-19 Vaccines / Genetic Vectors / SARS-CoV-2 / COVID-19 Topics: Vaccines Limits: Animals Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-020-3035-9

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Attenuated / Yellow Fever Vaccine / COVID-19 Vaccines / Genetic Vectors / SARS-CoV-2 / COVID-19 Topics: Vaccines Limits: Animals Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-020-3035-9